• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

    11/15/21 11:00:00 AM ET
    $CLRB
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLRB alert in real time by email

    SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer.

    Kazia Therapeutics Limited Logo (PRNewsfoto/Kazia Therapeutics Limited)

    In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States.

    Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clinic, this appointment is very timely. John is a highly experienced oncology and haematology drug developer who brings to Kazia a wealth of expertise, as well as a passion for improving the lives of patients with cancer."

    Dr. Friend gained his medical degree at Rutgers University (UMDNJ-Robert Wood Johnson) and also holds a BA in chemistry from Southern Methodist University. In a career spanning more than 25 years, he has worked across a wide range of therapeutic areas in roles spanning early clinical research through to medical affairs. Of note, he spent seven years with the US business unit of Helsinn Therapeutics, a leading European specialty pharmaceutical company, leaving as Senior Vice President of Medical and Scientific Affairs. Prior to joining Kazia, he was Chief Medical Officer at Cellectar Biosciences, Inc (NASDAQ:CLRB), a clinical-stage, oncology-focused biotech company based in Florham Park, NJ.

    Dr. Friend commented, "I look forward to working with Kazia colleagues to drive the company's pipeline forward toward its full potential.  Both paxalisib and EVT801 have enormous scope to address unmet needs in a number of different tumor types and I am pleased to be working with world-renowned cancer centers and their leading clinicians to develop these promising new therapies. I am delighted to join Kazia at such an exciting and pivotal time for the company."

    About Kazia Therapeutics Limited

    Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))) is an oncology-focused drug development company, based in Sydney, Australia.

    Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, paxalisib commenced recruitment to GBM AGILE, a pivotal study in glioblastoma, in January 2021. Eight additional studies are active in various forms of brain cancer. Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020.

    Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021.

    For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx.

    This document was authorized for release to the ASX by James Garner, Chief Executive Officer, Managing Director.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/kazia-therapeutics-appoints-john-friend-md-as-chief-medical-officer-301423685.html

    SOURCE Kazia Therapeutics Limited

    Get the next $CLRB alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CLRB
    $KZIA

    CompanyDatePrice TargetRatingAnalyst
    Kazia Therapeutics Limited
    $KZIA
    2/6/2025$3.00Buy
    Maxim Group
    Cellectar Biosciences Inc.
    $CLRB
    12/5/2024$13.00Buy
    Ladenburg Thalmann
    Kazia Therapeutics Limited
    $KZIA
    10/14/2021$18.00Buy
    Maxim Group
    More analyst ratings

    $CLRB
    $KZIA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Caruso James V bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 611% to 11,638 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:02:08 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Longcor Jarrod bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 361% to 12,768 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:01:18 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kolean Chad J bought $24,950 worth of shares (5,000 units at $4.99), increasing direct ownership by 353% to 6,418 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:00:13 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    $KZIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Kazia Therapeutics with a new price target

      Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00

      2/6/25 7:53:38 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ladenburg Thalmann resumed coverage on Cellectar Biosciences with a new price target

      Ladenburg Thalmann resumed coverage of Cellectar Biosciences with a rating of Buy and set a new price target of $13.00

      12/5/24 8:32:15 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Kazia Therapeutics with a new price target

      Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00

      10/14/21 8:02:40 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    $KZIA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Caruso James V bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 611% to 11,638 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:02:08 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Longcor Jarrod bought $49,900 worth of shares (10,000 units at $4.99), increasing direct ownership by 361% to 12,768 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:01:18 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Kolean Chad J bought $24,950 worth of shares (5,000 units at $4.99), increasing direct ownership by 353% to 6,418 units (SEC Form 4)

      4 - Cellectar Biosciences, Inc. (0001279704) (Issuer)

      7/3/25 8:00:13 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    $KZIA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Cellectar Biosciences Inc.

      EFFECT - Cellectar Biosciences, Inc. (0001279704) (Filer)

      7/2/25 12:15:15 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by Cellectar Biosciences Inc.

      424B4 - Cellectar Biosciences, Inc. (0001279704) (Filer)

      7/1/25 7:45:51 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form S-1/A filed by Cellectar Biosciences Inc.

      S-1/A - Cellectar Biosciences, Inc. (0001279704) (Filer)

      6/30/25 8:29:31 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    $KZIA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option

      FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the "Company"), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the closing of its previously announced underwritten public offering for gross proceeds of approximately $6.9 million prior to deducting underwriting commissions and offering expenses. The offering includes participation from healthcare dedicated funds and executive management. The offering is composed of (i) 1,045,000 Class A Units (which includes 180,000 Class A Units issued pursuant to the Underwriter's exercise of the over-allotmen

      7/2/25 4:15:00 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering

      FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB) (the "Company"), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses. The offering is comprised of (i) 865,000 Class A Units with each Class A Unit consisting of (a) one share of common stock and (b) one common warrant to purchase one share of common stock (the "Common Warrants"), and (ii) 335,000 Class B Units with each Class B Unit consisting of

      7/1/25 9:25:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)

    $CLRB
    $KZIA
    Leadership Updates

    Live Leadership Updates

    See more
    • Oncology Innovation Just Hit a Turning Point -- Here's What to Watch

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 30, 2025 /PRNewswire/ -- USA News Group News Commentary – The oncology landscape is being pulled in two directions. On one hand, U.S. cancer death rates continue to decline. On the other, global cases are expected to rise sharply—while early-onset diagnoses in younger patients are climbing at a troubling pace. At the same time, proposed federal budget cuts threaten to slash funding for the National Cancer Institute by up to 40%, raising concerns about the future of publicly funded research. With public resources under pressure, much of the innovation burden is shifting to the private sector, where a

      6/30/25 11:02:00 AM ET
      $ARAY
      $CLRB
      $ERAS
      $INTS
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

      SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer

      1/18/24 7:30:00 AM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Expands Commercialization Leadership Team Ahead of Pivotal Data for Iopofosine I-131 in Waldenstrom's Macroglobulinemia

      William Yoon Appointed Vice President, Medical Affairs Aaditya Nanduri Appointed Vice President, Business Strategy and Analytics FLORHAM PARK, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of targeted drugs for the treatment of cancer, is pleased to announce the appointment of William Yoon, PharmD, MBA/HCM as vice president, medical affairs and Aaditya Nanduri, MS, as vice president, business strategy and analytics ahead of the expected readout of top-line pivotal data for iopofosine I 131 in Waldenstrom's macroglobulinemia (WM) in Q4 2023. "

      10/17/23 8:00:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    $KZIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 4:47:59 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

      SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

      11/14/24 4:19:36 PM ET
      $KZIA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cellectar Biosciences Inc.

      SC 13G/A - Cellectar Biosciences, Inc. (0001279704) (Subject)

      11/14/24 1:26:20 PM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CLRB
    $KZIA
    Financials

    Live finance-specific insights

    See more
    • Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update

      Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data CLOVER WaM Major Response Rate for BTKi-Treated Patients 59.0% Company to hold webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., May 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2025, and provided a corporate update on its promising portfolio of clinical and pre-clini

      5/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025

      FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the Company will report financial results for the first quarter ended March 31, 2025, and provide a corporate update on May 13, 2025, at 8:30 a.m. Eastern Time. Conference Call & Webcast Details:Date:Tuesday, May 13, 2025Time:8:30 am Eastern TimeToll Free:1-800-717-1738Conference ID:53983Webcast:Click HERE A replay of the corporate presentation will be available on the Events section of the Company's Investor Relations website.

      5/7/25 8:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update

      Achieves alignment with U.S. Food and Drug Administration (FDA) on regulatory path for potential accelerated approval of iopofosine I 131 as a treatment for Waldenström macroglobulinemia (WM) Evaluating timing for Phase 1 solid tumor studies; Auger-emitting radioconjugate prepared for Phase 1b; plans to submit an IND for alpha-emitting radioconjugate; Company to host webcast and conference call at 8:30 AM ET today FLORHAM PARK, N.J., March 13, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced fin

      3/13/25 7:05:00 AM ET
      $CLRB
      Biotechnology: Pharmaceutical Preparations
      Health Care